Creo Medical Group PLC US Clinical Education Programme enters Phase II (7366L)
September 10 2019 - 1:01AM
UK Regulatory
TIDMCREO
RNS Number : 7366L
Creo Medical Group PLC
10 September 2019
Creo Medical Group plc
("Creo" or the "Company")
US Clinical Education Programme enters Phase II
First training course delivered by key US adopter trained by
Creo
Creo Medical Group plc (AIM: CREO), a medical device company
focused on the emerging field of surgical endoscopy, announces that
it has entered phase two of its Clinical Education Programme in the
US, with the successful completion of the first Speedboat training
course delivered by a US clinician trained as part of Creo's
programme. As part of this new phase, three additional US
clinicians have been trained by a US GI Endoscopists who performed
his first clinical case earlier this year (RNS 1927N, 16 January
2019) and practices at a major US hospital, which was one of the
first to place commercial orders for the Company's Speedboat
device.
Creo's Clinical Education Programme ensures that first adopters
of Speedboat, having been carefully mentored, can deliver training
in this emerging field of surgical endoscopy to their fellow
clinicians at a consistently high standard, safeguarding quality
control and ensuring best patient outcomes. This new phase of the
programme will see Creo establish the first in a series of US
training centres run by US key opinion leaders who have already
adopted Speedboat.
About Speedboat and CROMA
Speedboat is the first in a range of endoscopic minimally
invasive surgical devices to be cleared for use with the Company's
CROMA Advanced Energy platform, which uniquely combines bipolar
radiofrequency energy for precise tissue dissection along with
microwave energy for highly controlled coagulation and tissue
ablation. A growing number of GI Endoscopists in the UK, South
Africa, Mainland Europe and the US have now performed multiple
successful treatments using Speedboat, removing lesions in both
upper and lower GI cases.
Typically, instead of having to undergo surgery under general
anaesthetic, these patients only needed sedation and were treated
as day patients. As a result, Speedboat helps to reduce the risks
associated with alternative open, laparoscopic and existing
endoscopic procedures, reducing the length of stay in hospital for
the patient and the cost of treatment by transferring therapy from
the operating theatre to the endoscopy room.
Craig Gulliford, Creo's Chief Executive Officer, commented:
"To have one of our first key adopters in Phoenix, Arizona, who
was trained as part of the first wave of our US Clinical Education
Programme, now training fellow clinicians in the use of Speedboat
is a major milestone for the successful commercial roll-out of our
first product. It also marks the first in a series of training
centres to deliver these courses in sites across the US, and
similarly across other distributor markets for Creo.
"Whilst we remain in the early stages of roll-out, we expect to
see a cascade effect and an increasing number of endoscopists
trained consistently to the highest standards through our Clinical
Education Programme, resulting in the wider adoption of our
technology in the US."
Creo Medical Group plc
Richard Rees (CFO) +44 (0)129 160 6005
Cenkos Securities +44 (0)20 7397 8900
Stephen Keys / Cameron MacRitchie
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Lianne Cawthorne Mob: +44 (0)7515 909 238
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and radiofrequency energy to surgical endoscopy.
Creo has developed CROMA, an electrosurgical advanced energy
platform that combines bipolar RF for precise localised cutting and
microwave for controlled coagulation. This technology provides
clinicians with flexible, accurate and controlled surgical
solutions.
The Company's strategy is to bring its CROMA Advanced Energy
platform to market through a suite of medical devices which the
Company has designed, initially for the emerging field of GI
therapeutic endoscopy, an area with high unmet needs. The CROMA
Advanced Energy platform will be developed further for bronchoscopy
and laparoscopy procedures. The Company believes that its
technology can impact the landscape of surgery and endoscopy by
providing a safer, less-invasive and more cost-efficient option of
treatment.
For more information about Creo Medical please see our website,
investors.creomedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RESDBGDCCBGBGCC
(END) Dow Jones Newswires
September 10, 2019 02:01 ET (06:01 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From Jul 2023 to Jul 2024